2021
DOI: 10.1111/cas.15242
|View full text |Cite
|
Sign up to set email alerts
|

TCOF1 coordinates oncogenic activation and rRNA production and promotes tumorigenesis in HCC

Abstract: Treacle ribosome biogenesis factor 1 (TCOF1, also called Treacle) is a nucleolar factor which acts in collaboration with upstream binding factor (UBF) to regulate ribosomal DNA (rDNA) transcription in eukaryotes. 1 Haploinsufficiency of TCOF1 in mice leads to ribosome biogenesis perturbation, cell cycle arrest, increased cell death, and reduced proliferation and migration of neural crest cells. 2,3 Haploinsufficiency of TCOF1 also impairs the migration of human neural crest cells and mesenchymal stem cells. 4 … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
18
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 22 publications
(22 citation statements)
references
References 21 publications
4
18
0
Order By: Relevance
“…In summary, they suggest that upregulation of Treacle expression promotes carcinogenesis, stimulates proliferation, survival, and possibly contributes to radio-resistance, albeit with variation across different cancer types ( Figure 2 ). We observe significant upregulation of Treacle expression in 11 out of 14 different cancer types by analysis of paired normal and tumor data in agreement with other recently published studies ( Wu et al, 2021 ; Gu et al, 2022 ; Hu et al, 2022 ). Interestingly, in uterine corpus endometrial carcinoma, where Treacle expression was not increased, the highest frequency of TCOF1 mutations were identified by Gu et al, 2022 , possibly altering the properties of the expressed protein.…”
Section: Discussionsupporting
confidence: 93%
See 3 more Smart Citations
“…In summary, they suggest that upregulation of Treacle expression promotes carcinogenesis, stimulates proliferation, survival, and possibly contributes to radio-resistance, albeit with variation across different cancer types ( Figure 2 ). We observe significant upregulation of Treacle expression in 11 out of 14 different cancer types by analysis of paired normal and tumor data in agreement with other recently published studies ( Wu et al, 2021 ; Gu et al, 2022 ; Hu et al, 2022 ). Interestingly, in uterine corpus endometrial carcinoma, where Treacle expression was not increased, the highest frequency of TCOF1 mutations were identified by Gu et al, 2022 , possibly altering the properties of the expressed protein.…”
Section: Discussionsupporting
confidence: 93%
“…Several recent studies focusing on the prognostic and potential therapeutic value of Treacle in cancer reach conclusions in agreement with our data. Wu et al proposed a role for Treacle in oncogenic activation and promotion of tumorigenesis in human hepatocellular carcinoma (HCC) ( Wu et al, 2021 ). They found a positive correlation between Treacle expression levels and advanced pathological stages and histological grade in HCC, suggesting a role for Treacle in cancer progression.…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…Treacle upregulation is however emerging as a tumor promoting factor. Elevated Treacle levels correlated with poor prognosis, and shorter survival in different cancer types ( Gu et al, 2022 ; Hu et al, 2022 ; Wu et al, 2022 ). This could be attributed to Treacle’s function in facilitating rRNA transcription.…”
Section: Treacle In Cancermentioning
confidence: 99%